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Abstract
Background: Osteoarthritis (OA) is a slowly destructive process that may be influenced by a
nutritional mineral balance in the body.
Methods: This small, double blind, placebo controlled pilot study investigated the impact of
treatment with a natural multi-mineral supplement from seaweed (Aquamin) on 6 minute walking
distance (6 MWD), range of motion (ROM), and pain and joint mobility measured by the Western
Ontario and McMaster Universities (WOMAC) Osteoarthritis Index in subjects with moderate to
severe OA of the knee during gradual withdrawal of non-steroidal anti-inflammatory drugs
(NSAIDs) that were being used daily for pain management. Subjects (n = 29) with moderate to
severe OA of the knee were randomised to receive either Aquamin (2400 mg/d) or Placebo for up
to 12 weeks.
Results: Of the 29 subjects initially randomized, only 22 subjects proceeded to treatment due to
7 subjects not meeting study selection criteria at baseline. Fourteen subjects completed the study
and an ITT analysis (n = 22) of the data showed no significant differences in WOMAC scores
however, the data did reveal significant improvements in passive and active extension ROM (0.83°
± 1.54 vs. -1.54° ± 2.43; difference, 5.2° ± 2.2, p = 0.028) and 6 MWD (150 ± 48 ft vs. 12.5 ± 31.5
ft; difference, 136 ± 57 ft, p = 0.03) in the Aquamin group compared to the placebo group;
respectively, following a 50% reduction in NSAID use. The treatments were well tolerated and the
adverse event profiles were not significantly different between the groups.
Conclusion: This small preliminary study suggests Aquamin may increase range of motion and
walking distances in subjects with OA of the knee and may allow partial withdrawal of NSAIDs over
12 weeks of treatment. Additional research is needed to confirm these preliminary observations.
Trial registration: NCT00755482
Background
Osteoarthritis (OA), also called degenerative joint disease,
is a slow destructive process of the joint. Although the
exact biochemical cause of OA remains unknown, the
process usually begins when the joint structures are
abnormal or the stress placed on the joint surfaces is unu-
sually high. Much of the disease progression is due to
mechanical stress on the joint and over time the excessive
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stress can induce metabolic and structural changes in the
cartilage, bone and articular surfaces. In addition, bone
and joint abnormalities have been documented in devel-
oping countries and may be associated with nutritional
and developmental problems. OA is expected to affect
over 59 million people in the United States alone by the
year 2020 [1]. In industrialised countries, primarily older
people suffer from this disease which is aggravated by
increasing weight with age, increasingly sedentary life-
styles and the lack of adequate exercise regimes.
Non-steroidal anti-inflammatory drugs (NSAIDs) are fre-
quently employed to provide relief from symptoms of OA
but NSAID use is sometimes accompanied by unwelcome
side-effects including gastrointestinal distress, ulcer for-
mation and cardiovascular problems [2,3]. As a result,
glucosamine and other new anti-inflammatory com-
pounds showing reduced adverse effects are being
explored as possible treatments for OA [4-6]. Growing evi-
dence suggests that several minerals play an important
role in joint health. Naturally occurring minerals such as
magnesium, copper, manganese, selenium and zinc have
shown anti-inflammatory effects in both animal and
human studies. In a rat model of osteoarthritis, a defi-
ciency of dietary magnesium increased cartilage damage
[7]. Trace minerals such as boron and manganese have
been shown to reduce the symptoms and may slow the
pathogenesis of OA [8].
Calcium supplementation has been shown to improve
bone mineral density and recent reports suggest that cal-
cium may also play a role in ameliorating the symptoms
of OA. For example, the administration of 1 gram of cal-
cium ascorbate daily for a period of 14 days to 133
patients with OA of the knee and/or hip resulted in a sig-
nificant reduction in pain compared to placebo [9].
A calcium and magnesium-rich seaweed-derived multi-
mineral supplement, Aquamin, was investigated in two
similarly designed trials conducted in the same clinic at
the same time with two independent groups of subjects.
One trial was previously published showing improved
symptoms of OA including improved Western Ontario
and McMaster Universities (WOMAC) Osteoarthritis
Index [10] scores and walking distances in subjects con-
suming Aquamin compared to placebo [11]. Aquamin, is
a multi-mineral supplement, derived from the red algae
Lithothamnion corallioides which is rich in calcium and
magnesium and a variety of trace minerals including man-
ganese, selenium and zinc (Table 1). This preliminary
study was designed to investigate the potential for Aqua-
min to allow reduced NSAID usage over three months in
subjects with moderate to severe OA of the knee.
Methods
Study design
This small preliminary randomised, double blind, pla-
cebo controlled parallel group study investigated the
effect of Aquamin on NSAID dose reduction in subjects
with OA of the knee. We used anecdotal information
along with our experience from a previous study with a
similar endpoint to estimate the number of subjects that
might be needed for this small pilot study [12].
Ethics
This study was reviewed by Quorum Review Inc, a central
IRB (Seattle, WA), performed in compliance with all the
applicable regulations and guidelines (e.g. Good Clinical
Practice Guidelines, the Declaration of Helsinki,
21CFR50-Protection of Human Subjects and 21CRF56-
Institutional Review Boards) and was monitored and
audited according to Minnesota Applied Research Center
Standard Operation Procedures (SOPs). Subject data was
kept confidential and study records were stored in a
locked and secure storage area.
Study center and subject selection
This study was conducted at the Minnesota Applied
Research Center (Edina, MN). Subjects of either gender
were included if they voluntarily gave informed consent,
were ambulatory, 35–75 years old, with normal digestion
and absorption and were diagnosed with symptomatic
moderate to severe OA of the knee according to their pre-
vious medical history and the modified clinical criteria of
the American College of Rheumatology [13]. All subjects
were required to have a WOMAC total scores ≤ 75 at entry
and were currently taking NSAIDs daily for pain manage-
ment. The target knee was identified by physical examina-
tion as the most severely affected knee for each subject
and the cut off point for the WOMAC score was enforced
Table 1: Typical mineral composition of Aquamin*
Mineral Dry salt weight
Calcium 34%
Magnesium 2.4%
Phosphorous 0.08%
Potassium 0.7%
Sulphur 0.67%
Iron 915 ppm
Boron 16.5 ppm
Sodium 0.225%
Manganese 125 ppm
Cobalt 0.1 ppm
Copper 10 ppm
Zinc 26.1 ppm
Selenium 1 ppm
* Aquamin contains a wide spectrum of trace minerals assimilated 
from sea water. Aquamin is a natural ingredient and trace mineral 
levels may vary over time.Nutrition Journal 2009, 8:7 http://www.nutritionj.com/content/8/1/7
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as a means of standardizing the extent of pain and immo-
bility in the small number of subjects recruited for this
trial. A waiver to the selection criteria was made for one
subject who had a WOMAC score of 76 and was enrolled
in the trial.
Subjects were excluded from this trial if they had rheuma-
toid arthritis, gout, pseudogout, Paget's disease, seizure
disorder, insulin dependent diabetes mellitus, uncon-
trolled hypertension, unstable cardiovascular disease,
active hepatic or renal disease, active cancer, HIV infec-
tion; if they required prescription drugs to control pain; if
they had other clinical trial or experimental treatments in
the past 3 months; if they were pregnant, lactating or at
risk of becoming pregnant; or if they had intramuscular or
systemic corticosteroid administration within 1 month,
intra-articular corticosteroid injection within 2 months or
intra-articular hyaluronic acid injection within 4 months
prior to study enrollment.
Study visits and treatments
The study was conducted over 14 weeks with a total of 6
visits to the study centre at -2 (screening), 0 (baseline), 2,
4, 8 and 12 weeks on treatment. During the initial two-
week screening period (-2 to 0 weeks), subjects were asked
to discontinue any prescription, over-the-counter or alter-
native therapy treatments for pain management but were
allowed to use their preferred NSAID for pain manage-
ment. In order to establish a standardised calcium intake
across all treatments, subjects were asked not to change
their usual dietary patterns during this trial except to con-
sume a diet with approximately 600 mg calcium per day
(e.g. two dairy servings) which was estimated to be 40–
60% of their Recommended Daily Allowance (RDA) for
calcium (depending on their age). Subjects were also
asked to maintain the same amount of exercise through-
out the study even if their joint pain was reduced. Quali-
fied subjects were randomised (1:1) to receive either
placebo or Aquamin and the trial activities remained dou-
ble blinded throughout the trial to avoid bias. The sub-
jects were blindly allocated to one of two treatment
groups, according to a randomisation table, in the order
of their enrollment in the study. The computer generated
randomisation table was created by an independent stat-
istician and the investigators were not aware of the group
code assignments. A third party was responsible for label-
ling the test article and placebo according to the subject
number and the randomisation table and the group code
assignments.
At the baseline visit, all subjects received pre-packaged
two-piece hard shell capsules containing either Aquamin
(267 mg Aquamin + 167 mg maltodextrin) (34% calcium,
88.1 mg) or placebo (434 mg maltodextran). The bottles
(and the capsules inside) appeared identical and subjects
were instructed to consume three capsules, with a glass of
water, three times per day. After taking either Aquamin or
placebo for 2 weeks (0–2 weeks), subjects were asked to
reduce NSAID use by 50% for a period of 2 weeks (2–4
weeks) and to eliminate NSAID use completely after 4
weeks and for the remainder of the study (4–12 weeks).
Pain was managed with acetaminophen (325 mg per tab-
let with 1–2 tablets to be taken every 4–6 hours as needed
for pain).
Study measurements
Vital signs, adverse events and the amounts of acetami-
nophen used for pain were assessed at each visit. Labora-
tory tests were performed and subjects completed
WOMAC questionnaires as well as 6-minute walking dis-
tance (6 MWD) and range of motion (ROM) tests. Subject
compliance was assessed at each visit by pill count, inter-
view, and review of the medication diary. The WOMAC
Osteoarthritis Index is a validated questionnaire includ-
ing scores for pain, stiffness and activity as well as a com-
posite (total) score. The 6 MWD was conducted by
marking off a 100-foot distance in an interior hallway and
asking subjects to walk as far as they could as quickly as
possible over 6 minutes. The total distance was measured
and recorded. ROM tests for the effected knee were meas-
ured using a goniometer.
Statistical analyses
An independent statistician analysed the data using t-tests
(for single between-group comparisons), ANCOVA (for
between-group comparisons at specific timepoints, using
baseline score as a covariate) and a mixed linear regres-
sion model on repeated measures data (for between-
group comparisons across all timepoints) to analyze data
for an Intent to Treat Group (including all subjects
enrolled and treated in this trial with values imputed for
their Last Observation Carried Forward (LOCF) for any
subjects who did not complete the trial) and a Compl-
eter's Group (including only data from subjects who com-
pleted the trial per protocol).
Results
Subject enrollment and disposition
This study was initially designed to enroll 50 volunteers;
however, recruitment was terminated after 29 subjects
were screened due to a lack of volunteers. The subjects
expressed a fear that they would have OA pain symptoms
following the complete discontinuation of NSAIDs as
required for the study. Of the initial 29 subjects enrolled,
13 were assigned to the Aquamin group, 15 were assigned
to the Placebo group, and one was not randomized to a
group assignment. Seven (7) of the 29 subjects did not to
fit the trial protocol requirements at their baseline visit
and were discontinued from the study. Of these seven
subjects, 5 were allocated to the Aquamin arm, 1 was allo-Nutrition Journal 2009, 8:7 http://www.nutritionj.com/content/8/1/7
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cated to the placebo arm and one was not yet randomized
to a group assignment. Therefore, 22 of the initial 29 sub-
jects went on to the treatment phase of the trial, with 8
subjects allocated to the Aquamin arm and 14 subjects
allocated to the placebo arm.
A total of 14 (64%) of the 22 treated subjects completed
the trial with treatment for the expected 12 weeks (84
days) (Table 2). Eight (36%) subjects withdrew from the
trial including five subjects from the placebo arm and
three from the Aquamin arm. Two subjects withdrew from
the Aquamin arm at days 1 and 10 of treatment (prior to
any reduction in NSAID usage) because they were unable
to maintain adequate compliance with one or more
aspects of the protocol and one subject withdrew from the
Aquamin arm on day 65 due to increasing knee pain. In
contrast, five subjects withdrew from the placebo arm due
to increasing knee pain in the latter stages of the trial (41
+/- 14 days [mean +/- SD] – at 28, 32, 39, 41, and 64 days)
when NSAID use had been completely eliminated.
Although considerably more subjects withdrew due to
increasing pain levels in the placebo group (n = 5) than
the Aquamin group (n = 1) this was not statistically signif-
icant (Figure 1).
Baseline characteristics
No significant differences were seen between the groups
for any of the measured variables at baseline (0 weeks/V2;
Table 3). Of the 22 subjects receiving treatment in this
trial, seven females and one male received Aquamin (n =
8) whereas eight females and six males received placebo
(n = 14). The mean age was 62.5 vs. 62.9 years and the
mean weight was 91 vs. 94 kilograms for the Aquamin
versus placebo groups respectively.
Trial flow chart Figure 1
Trial flow chart.
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Test article and rescue medications
No significant differences were found between the two
groups for test article or rescue medication consumption
at any single timepoint or over time in this trial. Although
not statistically significant, the use of pain meds increased
over time from V4 to V5 to V6 for both groups indicating
parallel courses for both groups over the time period of
this trial.
WOMAC
No significant differences were found between the two
groups for WOMAC pain, stiffness, activity or composite
scores (Table 4).
ROM
No differences were found between the two groups when
ROM scores were compared across all available visits;
however significant differences were found when changes
from baseline to specific time endpoints were compared
separately using a conventional univariate analysis of var-
iance (ANCOVA) approach. Groups were compared at
each treatment timepoint (V3, V4, V5, V6) and LOCF sep-
arately while adjusting for baseline (V2) score. Groups dif-
fered significantly in the change from V2 (baseline) to V4
(one month on treatment and after two weeks with
NSAID dose at 50%). Significantly higher ROM for pas-
sive and active extension (0.83° ± 1.54 vs. -1.54° ± 2.43;
difference, 5.2° ± 2.2, p = 0.028) were recorded for the
Aquamin group (Figure 2 and Table 4) following the 50%
reduction in NSAID use. No statistically significant
changes were noted between the groups for active or pas-
sive flexion ROM.
6 MWD
No differences were found in 6 MWD when scores were
compared across all visits from V2 to V6; however, analy-
sis of each time-point separately while adjusting for the
baseline (V2) score showed significant differences
between the two groups in the change from V2 (baseline)
to V4 (one month on treatment and after two weeks with
NSAID dose at 50%). The distance covered during a 6
minute timed walk was significantly improved within the
Aquamin group compared to the placebo group (150 ± 48
ft vs. 12.5 ± 31.5 ft; difference, 136 ± 57 ft, p = 0.03) (Fig-
ure 3 & Table 4) indicating a significant improvement in
the Aquamin treated group when NSAID use was reduced
by 50%.
Adverse events
All treatments were well tolerated and no serious adverse
events were reported in this trial. Table 5 shows the 31
adverse events (AE) that were reported with 10 AE in the
Aquamin group and 21 in the placebo group. One adverse
event was scored as at least possibly related to the study
due to the timing of the gastrointestinal-related distur-
bance and the cessation of the problem with end of treat-
ment (however this subject was in the placebo group). All
AE have completely resolved.
Discussion
This preliminary study was designed to investigate the
potential of a marine derived multi-mineral supplement
(Aquamin) to allow for reduced NSAID usage over three
months in subjects with moderate to severe OA of the
knee. Early in the trial, six subjects discontinued participa-
tion because subjects described increased knee pain and
did not wish to continue in the trial. These subjects were
treated on average until day 45 +/- 16 days (mean +/- SD)
(range 28 to 65 days) and the timing of their withdrawal
coincided with the time they were stopping their NSAID
use (i.e. after four weeks or 28 days on study treatment).
Of interest, five of the six subjects who withdrew due to
increased knee pain were on placebo and only one was
receiving Aquamin. The five subjects on placebo withdrew
at the following days of treatment: 28, 32, 39, 41, and 64
days and the one subject on Aquamin had the longest
time on treatment (65 days) before discontinuation. This
Table 2: Subject disposition
Trial ID Placebo Aquamin F Total
Subjects Treated 14 8 22
Subjects Completed 9 5 14
Number Withdrawn 5 3 8
Withdrawn – Days in Trial * 41 (14) 25 (35) 35 (23)
*Values are given as the mean (standard deviation)
Table 3: Baseline demographics
Measurement Placebo
N = 14
Aquamin
N = 8
P values*
Gender (F/M) 8/6 7/1 0.141
Age 62.9 (11.4)** 62.5 (5.3) 0.934
Height 68.3 (3.8) 65.5 (3.7) 0.144
Weight 94 (24) 91 (23) 0.753
Systolic Blood Pressure 142 (22) 133 (23) 0.394
Diastolic Blood Pressure 83 (13) 78 (12) 0.414
Pulse 69 (17) 78 (13) 0.183
Temperature 97.9 (1.0) 97.9 (0.4) 0.857
WOMAC – pain 60 (15) 54 (17) 0.428
WOMAC – stiffness 54 (21) 45 (15) 0.294
WOMAC – activity 57 (18) 49 (19) 0.327
WOMAC – composite 58 (16) 50 (18) 0.318
ROM – PF 76 (6) 73 (6) 0.661
ROM – AF 78 (14) 73 (16) 0.471
ROM – PE 170 (6) 172 (6) 0.497
ROM – AE 170 (6) 172 (6) 0.497
6 MWD 1289 (281) 1318 (267) 0.819
*P value based on t-test with equal variance assumed (except gender 
which was analysed with chi square analysis). **except for gender, 
values are given as the Mean (standard deviation)Nutrition Journal 2009, 8:7 http://www.nutritionj.com/content/8/1/7
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suggests that none of the subjects dropped out of the trial
when they were at 50% of their NSAID dose; however,
27% (6/22) withdrew due to increasing pain after stop-
ping their NSAID use entirely. Although not statistically
significant, 36% (5/14) of subjects withdrew from the pla-
cebo group while only 13% (1/8) withdrew from the
Aquamin group due to increasing pain after stopping their
NSAID use. Although more research is needed, these data
suggest that Aquamin treatment compared to placebo
may have been helpful to keep people in the trial (with
less pain in the affected knee) while they reduced their
NSAID use by 50–100%.
Table 4: Changes in study endpoints from baseline to visit 4
Measurement Placebo**
N = 14
Aquamin**
N = 8
Group differences*** P values*
WOMAC – pain 5.38(2.80) 10.83(8.30) 3.5(7.1) 0.63
WOMAC – stiffness 4.81(4.37) 10.42(12.67) 1.9(8.8) 0.83
WOMAC – activity 6.54(2.16) 14.72(9.04) 5.5(6.8) 0.43
WOMAC – composite 6.17(1.96) 13.55(8.98) 4.9(6.7) 0.47
ROM – PF 3.84(2.48) 6.67(3.57) 2.7(4.3) 0.54
ROM – AF 1.92(2.63) 8.33(4.22) 6.0(4.8) 0.23
ROM – PE -1.54(2.43) 0.83(1.54) 5.2(2.2) 0.028
ROM – AE -1.54(2.43) 0.83(1.54) 5.2(2.2) 0.028
6 MWD 12.5(31.5) 150(48) 136(57) 0.03
* P value based on ANCOVA group effect. ** mean change (SE). ***mean group difference in change (SE) based on ANCOVA estimated marginal 
means
Active and passive ROM over time Figure 2
Active and passive ROM over time. Change (Degrees) in ROM over 12 weeks of treatment.Nutrition Journal 2009, 8:7 http://www.nutritionj.com/content/8/1/7
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Of interest, placebo and Aquamin treatments were signif-
icantly different in the change from V2 (baseline) to V4
(one month on treatment and after two weeks with
NSAID dose at 50%) with higher adjusted mean values for
ROM for passive and active extension (173° vs. 168°; p =
0.028) as well as a greater six-minute walking distance
(1408 ft vs. 1295 ft; p = 0.03) for subjects on Aquamin
compared to placebo. This was an improvement of 8.7%
over the distance walked at baseline. Although, these dis-
tances appear to be small, our subjects with severe OA
indicated the ability to walk even a little bit further was
important to them. It is interesting to underline that these
significant results at V4 compared to V2 were recorded not
only following Aquamin treatment but also while NSAID
dosage was reduced by 50%. These results suggest that
Aquamin may provide some improved function in the set-
ting of a 50% reduced but not eliminated NSAID dose.
It should be noted that the positive results did not con-
tinue once NSAID use was abolished completely. Thus,
Aquamin cannot entirely replace NSAIDs as a treatment
for OA. However, Aquamin may allow for a reduced need
for NSAIDs which may have substantial health benefits
including a reduction in many of the adverse and well
documented side effects of NSAIDS. Further study is
needed to verify this information and to explore the abil-
ity of Aquamin to improve walking distance and range of
motion for subjects with osteoarthritis of the knee.
The limitations to this study include the short duration of
treatment (12 weeks) and limited sample size; however,
the extent of the daily pain endured by sufferers of OA is
highlighted by the fear and reluctance of these subjects to
Walking distance over time Figure 3
Walking distance over time. Change in distance (Feet) walked over 12 weeks of treatment.
Table 5: Adverse events
Item Placebo Aquamin Total
Number subjects treated 14 8 22
Total number of adverse events 21 10 31
-upper respiratory events 3 2 5
-gastrointestinal events 4 1 5
-food reaction 0 1 1
-hypertension/cardiovascular 1 1 2
-musculoskeletal events 4 3 7
-neurological events 2 0 2
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completely eliminate NSAID usage for eight consecutive
weeks. Although the differences reported are small, to the
subjects with moderate to severe OA, the ability to walk
and move more freely is of enormous importance. Addi-
tional studies of longer treatments in a greater number of
subjects are necessary to fully explore the treatment effect
of Aquamin in OA.
Aquamin is composed of multiple minerals and the
'active ingredient' for the complex is difficult to deter-
mine. A number of minerals in Aquamin may have anti-
inflammatory and anti-oxidant properties which may
directly and/or indirectly influence the efficacy of this
unique complex. While the prominent mineral present in
Aquamin is calcium (dosage = 80% calcium RDA) its role
in joint health remains unclear and warrants further
study. Magnesium, was given at the daily dosage provid-
ing 14% (male) to 18% (female) US RDA. This may have
influenced OA symptoms by affecting the utilization of
calcium or by potentially reducing the inflammation
around the affected joint. Both manganese and selenium
were given at the daily dosage providing up to 16% and
4% of their RDA respectively. Both of these trace minerals
have been reported to reduce the appearance of osteoar-
thritic lesions and reduce the severity of symptoms in OA.
Conclusion
This study suggests a potential treatment effect for Aqua-
min among sufferers of moderate to severe OA and a pos-
sible reduction in the need for NSAIDs to manage the
symptoms of OA. These preliminary findings warrant fur-
ther study.
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